Brisbane, Australia, 24 April 2018 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has signed a letter of intent (LOI) with a German private hospital network to run a pilot project to test the applicability and integration of ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease, within a German hospital structure.
The partners will work together to design and run a six-month pilot project at one or more of the network’s hospitals in Germany at no-cost to ResApp. The pilot project must be started by November 1, 2018 and ResApp will not receive revenue from the pilot. At the completion of the project ResApp has agreed to grant the network an exclusive, no-cost license to use ResAppDx in their hospitals in Germany for six months and a non-exclusive, no-cost license for an additional six months. Successful completion of the pilot may lead to the network negotiating a commercial licensing agreement for use in their hospitals. Under the LOI neither party has taken on any obligations regarding ResAppDx following the pilot project and subsequent no-cost license periods.
“We are excited to be working with a leading German hospital network. This gives us a unique opportunity to work closely with European clinicians and hospital executives, providing us with invaluable insight into European clinical practice and hospital operations,” said Tony Keating, CEO and Managing Director of ResApp Health. “We expect this project to significantly accelerate the commercialisation of ResAppDx in Europe.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. ResApp has adult and paediatric clinical studies underway at leading hospitals in the United States and Australia with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.